Active substance
Glyceryl trinitrate
- SFDA 14
- US FDA 65
- Health Canada 16
- US price lines 16
- NHS prices 7
- WHO EML 1
- Safety 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| GLYCERYL TRINITRATE 50MG-10ML I-V AMP | 5 mg/ml | Solution for injection · Intravenous use | 5 Ampoule | SAR 131.10 | Generic · Prescription | HOSPIRA UK LIMITED | Valid |
| NITRODERM TTS 5 PATCHES | 25 mg | Transdermal patch · Transdermal use | 30 Sachet | SAR 58.30 | NCE · Prescription | Sandoz Pharmaceuticals | Valid |
| NITRODERM TTS 5 PATCHES | 25 mg | Transdermal patch · Transdermal use | 10 Sachet | SAR 17.60 | NCE · Prescription | Sandoz Pharmaceuticals | Valid |
| NITRODERM TTS-10 SYSTEM | 50 mg | Transdermal patch · Topical | 10 Sachet | SAR 33.75 | NCE · Prescription | Sandoz Pharmaceuticals | Valid |
| NITRODERM TTS-10 SYSTEM | 50 mg | Transdermal patch · Topical | 30 Sachet | SAR 62.60 | NCE · Prescription | Sandoz Pharmaceuticals | Valid |
| Netrosan | 0.4 % (W/W) | Rectal ointment · Topical | 1 Tube | SAR 76.45 | Generic · Prescription | Sana pharmaceutical Industry | Valid |
| Retrosin Ointment | 0.4 % | Rectal ointment · Topical | 1 Tube | SAR 91.40 | NCE · Prescription | PHILADELPHIA PHARMACEUTICALS | Valid |
| GLYCERYL TRINITRATE 50MG-10ML I-V AMP | 5 mg/ml | Solution for injection · Intravenous use | 5 Ampoule | SAR 131.10 | Generic · Prescription | HOSPIRA AUSTRALIA | Withdrawn by MAH · Not Marketed |
| NITRO-DUR | 15 mg | Transdermal patch · Transdermal use | 10 Box | SAR 31.70 | NCE · Prescription | SCHERING-PLOUGH | Withdrawn by MAH · Not Marketed |
| NITRO-DUR | 10 mg | Transdermal patch · Transdermal use | 10 Box | SAR 39.10 | NCE · Prescription | SCHERING-PLOUGH | Withdrawn by MAH · Not Marketed |
| NITRO-DUR | 5 mg | Transdermal patch · Transdermal use | 10 Box | SAR 23.50 | NCE · Prescription | SCHERING-PLOUGH | Withdrawn by MAH · Not Marketed |
| NITROGLYCERINE INJ F.T.V.5 ML 25 MG | 5 mg/ml | Solution · Intravenous use | 1 Vial | SAR 36.85 | NCE · Prescription | HOSPIRA INC | Withdrawn by MAH · Not Marketed |
| NITROGLYCERINE INJ F.T.V.50MG-10 ML | 5 mg/ml | Solution · Intravenous use | 1 Vial | SAR 50.45 | NCE · Prescription | HOSPIRA INC | Withdrawn by MAH · Not Marketed |
| NITROSTAT 0.6 MG TAB | 0.6 mg | Tablet · Oral use | 100 Blister | SAR 5.70 | NCE · Prescription | PARK-DAVIS | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
HYPERTENSION; ST-WAVE ELEVATED MYOCARDIAL INFARCTION (STEMI)
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NITROGLYCERIN | 2% | ointment · transdermal | FOUGERA PHARMS INC | Prescription | 28 May 1981 |
| NITROLINGUAL PUMPSPRAY | 0.4MG/SPRAY | spray, metered · sublingual | POHL BOSKAMP | Prescription | 31 Oct 1985 |
| NITRO-DUR | 0.1MG/HR; 0.2MG/HR; 0.3MG/HR; 0.4MG/HR; 0.6MG/HR; 0.8MG/HR | film, extended release · transdermal | USPHARMA | Prescription | 10 Dec 1985 |
| NITROGLYCERIN | 5MG/ML | injectable · injection | AM REGENT | Prescription | 24 May 1988 |
| NITROGLYCERIN IN DEXTROSE 5% | 10MG/100ML; 20MG/100ML; 40MG/100ML | injectable · injection | BAXTER HLTHCARE | Prescription | 29 Dec 1989 |
| NITROGLYCERIN | 0.6MG/HR; 0.4MG/HR; 0.2MG/HR; 0.1MG/HR | film, extended release · transdermal | MYLAN TECHNOLOGIES | Prescription | 30 Aug 1996 |
| NITROGLYCERIN | 0.2MG/HR | film, extended release · transdermal | ZYDUS PHARMS | Prescription | 30 Oct 1998 |
| NITROGLYCERIN | 0.4MG/HR; 0.1MG/HR | film, extended release · transdermal | ZYDUS PHARMS | Prescription | 30 Oct 1998 |
| NITROGLYCERIN | 0.6MG/HR | film, extended release · transdermal | ZYDUS PHARMS | Prescription | 30 Oct 1998 |
| NITROSTAT | 0.3MG; 0.4MG; 0.6MG | tablet · sublingual | VIATRIS | Prescription | 1 May 2000 |
| NITROMIST | 0.4MG/SPRAY | aerosol, metered · sublingual | EVUS | Prescription | 2 Nov 2006 |
| NITROGLYCERIN | 0.4MG/SPRAY | spray, metered · sublingual | PADAGIS ISRAEL | Prescription | 20 Sep 2013 |
| NITROGLYCERIN | 0.3MG; 0.4MG; 0.6MG | tablet · sublingual | DR REDDYS | Prescription | 26 Aug 2016 |
| NITROGLYCERIN | 0.3MG; 0.4MG; 0.6MG | tablet · sublingual | GLENMARK SPECLT | Prescription | 19 Sep 2017 |
| NITROGLYCERIN | 0.3MG; 0.4MG; 0.6MG | tablet · sublingual | NATCO | Prescription | 30 Apr 2019 |
| NITROGLYCERIN | 0.3MG; 0.4MG; 0.6MG | tablet · sublingual | RUBICON RESEARCH | Prescription | 3 May 2021 |
| NITROGLYCERIN | 0.3MG; 0.4MG; 0.6MG | tablet · sublingual | AUROBINDO PHARMA | Prescription | 26 Oct 2023 |
| NITROGLYCERIN | 0.3MG; 0.4MG; 0.6MG | tablet · sublingual | MANKIND PHARMA | Prescription | 5 Dec 2023 |
| NITROGLYCERIN | 0.4% | ointment · intra-anal | COSETTE PHARMS NC | Prescription | 16 Feb 2024 |
| NITROGLYCERIN | 0.3MG; 0.4MG; 0.6MG | tablet · sublingual | PHARMOBEDIENT | Prescription | 15 Oct 2024 |
| NITROGLYCERIN | 0.4% | ointment · intra-anal | TP ANDA HOLDINGS | Prescription | 29 Nov 2024 |
| NITROGLYCERIN | 0.4% | ointment · intra-anal | ENCUBE | Prescription | 16 Dec 2024 |
| NITROGLYCERIN | 2% | ointment · transdermal | ENCUBE | Prescription | 15 Apr 2025 |
| NITROGLYCERIN | 0.4% | ointment · intra-anal | AMVIKA | Prescription | 18 Dec 2025 |
| NITROGLYCERIN | 0.4% | ointment · intra-anal | PADAGIS ISRAEL | Prescription | 6 Jul 2026 |
40 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| MYLAN-NITRO PATCH 0.2 | 02407442 | 0.2 MG / HOUR | PATCH (EXTENDED-RELEASE) · TRANSDERMAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-NITRO PATCH 0.4 | 02407450 | 0.4 MG / HOUR | PATCH (EXTENDED-RELEASE) · TRANSDERMAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-NITRO PATCH 0.6 | 02407469 | 0.6 MG / HOUR | PATCH (EXTENDED-RELEASE) · TRANSDERMAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-NITRO PATCH 0.8 | 02407477 | 0.8 MG / HOUR | PATCH (EXTENDED-RELEASE) · TRANSDERMAL | MYLAN PHARMACEUTICALS ULC |
| NITRO-DUR 0.2 | 01911910 | 0.2 MG / HOUR | PATCH (EXTENDED-RELEASE) · TRANSDERMAL | USPHARMA LTD |
| NITRO-DUR 0.4 | 01911902 | 0.4 MG / HOUR | PATCH (EXTENDED-RELEASE) · TRANSDERMAL | USPHARMA LTD |
| NITRO-DUR 0.6 | 01911929 | 0.6 MG / HOUR | PATCH (EXTENDED-RELEASE) · TRANSDERMAL | USPHARMA LTD |
| NITRO-DUR 0.8 | 02011271 | 0.8 MG / HOUR | PATCH (EXTENDED-RELEASE) · TRANSDERMAL | USPHARMA LTD |
| NITROJECT | 00778869 | 50 MG / 10 ML | SOLUTION · INTRAVENOUS | JUNO PHARMA CANADA INC. |
| NITROLINGUAL PUMPSPRAY | 02231441 | 0.4 MG / ACT | METERED-DOSE PUMP · SUBLINGUAL | G POHL-BOSKAMP GMBH & CO KG |
| NITROSTAT | 00037613 | 0.3 MG | TABLET · SUBLINGUAL | BGP PHARMA ULC |
| NITROSTAT | 00037621 | 0.6 MG | TABLET · SUBLINGUAL | BGP PHARMA ULC |
| RHO-NITRO PUMPSPRAY | 02238998 | 0.4 MG / ACT | METERED-DOSE PUMP · SUBLINGUAL | SANDOZ CANADA INCORPORATED |
| TRINIPATCH 0.2 | 02230732 | 0.2 MG / HOUR | PATCH · TRANSDERMAL | KNIGHT THERAPEUTICS INC. |
| TRINIPATCH 0.4 | 02230733 | 0.4 MG / HOUR | PATCH · TRANSDERMAL | KNIGHT THERAPEUTICS INC. |
| TRINIPATCH 0.6 | 02230734 | 0.6 MG / HOUR | PATCH · TRANSDERMAL | KNIGHT THERAPEUTICS INC. |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | NITRO-BID 2% OINTMENT | $2.42188 | per GM | 23 Sep 2026 |
| US NADAC | NITRO-BID 2% OINTMENT | $1.23629 | per GM | 23 Sep 2026 |
| US NADAC | NITRO-BID 2% OINTMENT | $1.22466 | per GM | 23 Sep 2026 |
| US NADAC | NITRO-DUR 0.3 MG/HR PATCH | $50.49727 | per EA | 19 Aug 2026 |
| US NADAC | NITROGLYCERIN 0.1 MG/HR PATCH | $0.49331 | per EA | 23 Sep 2026 |
| US NADAC | NITROGLYCERIN 0.2 MG/HR PATCH | $0.59034 | per EA | 23 Sep 2026 |
| US NADAC | NITROGLYCERIN 0.3 MG TABLET SL | $0.06315 | per EA | 23 Sep 2026 |
| US NADAC | NITROGLYCERIN 0.4 MG TABLET SL | $0.12724 | per EA | 23 Sep 2026 |
| US NADAC | NITROGLYCERIN 0.4 MG TABLET SL | $0.07873 | per EA | 23 Sep 2026 |
| US NADAC | NITROGLYCERIN 0.4 MG/HR PATCH | $0.72064 | per EA | 23 Sep 2026 |
| US NADAC | NITROGLYCERIN 0.4% OINTMENT | $8.3149 | per GM | 23 Sep 2026 |
| US NADAC | NITROGLYCERIN 0.6 MG TABLET SL | $0.08428 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Glyceryl trinitrate 0.4% rectal ointment | £39.30 | 30 gram | 1 Oct 2026 |
| NHS Drug Tariff | Glyceryl trinitrate 10mg/24hours transdermal patches | £14.06 | 28 patch | 1 Oct 2026 |
| NHS Drug Tariff | Glyceryl trinitrate 400micrograms/dose pump sublingual spray | £2.75 | 75 dose | 1 Oct 2026 |
| NHS Drug Tariff | Glyceryl trinitrate 400micrograms/dose pump sublingual spray | £3.41 | 180 dose | 1 Oct 2026 |
| NHS Drug Tariff | Glyceryl trinitrate 400micrograms/dose pump sublingual spray | £3.78 | 200 dose | 1 Oct 2026 |
| NHS Drug Tariff | Glyceryl trinitrate 500microgram sublingual tablets | £16.35 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Glyceryl trinitrate 5mg/24hours transdermal patches | £12.77 | 28 patch | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 12.1. Antianginal medicines · core
Angina pectoris
Oral > Solid: 500 µg sublingual tablet
Safety signals and safety-related labeling changes
- US FDA 24 Jun 2022 NITROMIST — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 30 Jul 2018 NITROLINGUAL PUMPSPRAY — safety-related labeling change
Labeling sections changed: Drug Interactions; Use in Specific Populations - US FDA 24 Jan 2018 NITROSTAT — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.